Date:5/31/2011

n in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xi) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Current Report on Form 8-K filed with the SEC on April 6, 2011. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Company Contact:
www.inspire-md.com
Jonina Ohayon
Marketing Director
jonina@inspire-md.com
OTC BB: NSPR

Investor Contact:
Jeffrey Stanlis'/>"/>

SOURCE InspireMD, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Akron Relationship with Israeli Incubator, Targetech, Shows Promise
2. Neusoft to Invest in Israeli Medical Solutions Company for Accelerating Expansion in Global Healthcare Service Market
3. Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
4. Kensey Nash Announces New Unsecured Revolving Credit Facility
5. Applied Isotope Technologies Opens New Facility in PLSG Life Sciences Campus
6. MedPro Imaging Expands Operations With Opening of Dedicated Advanced Transducer Repair Facility
7. Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
8. NeoStems Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility
9. Leading Rehab Facility Urges Patients Not to Stop Taking Antidepressants After New Study Suggests Increased Risk of Heart Attacks and Strokes
10. AAIPharma Services Announces Compendial Testing Facility Expansion
11. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank